AAX Biotech Appoints Patrik Strömberg to Board of Directors
AAX Biotech has appointed Patrik Strömberg to its Board of Directors, adding over two decades of pharmaceutical industry experience to its leadership team.
AAX Biotech, a Swedish biotechnology startup focused on next-generation antibody therapeutics, has appointed Patrik Strömberg to its Board of Directors. This move is part of the company's strategic expansion and aims to bolster its collaborations with biotech and pharmaceutical partners.
Strömberg brings more than 20 years of experience from the pharmaceutical sector, with a strong background in research and development, innovation management, and business development. His previous roles include key positions at companies such as AstraZeneca and Biovitrum/Sobi. He currently serves as CEO of AnaCardio and holds a PhD in Biochemistry from Karolinska Institutet, along with an MBA from Stockholm University.
The company utilizes its proprietary technologies, Seqitope™ and Opti-mAb™, to enhance the performance and developability of antibody-based therapeutics. AAX Biotech aims to address unmet needs in this rapidly growing market.
AAX Biotech believes Strömberg's expertise will be instrumental in accelerating growth and strengthening its technological capabilities for the global market. The company was founded by experts from Karolinska Institutet.